Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Pursuant to the terms of the DRL Supply Agreement, we will in-license DRL's proposed abatacept biosimilar for use in the development of our combination product for neurodegenerative diseases COYA 302.”
FILING10-K0001193125-26-107281cik 0001835022
“In addition, COYA 201 requires a tangential flow filtration technology sourced from Repligen.”
FILING10-K0001193125-26-107281cik 0001835022
“For example, to image the exosomes we will rely on Malvern, to measure the size of the exosomes we will rely on Izon, for western blotting we will rely on ThermoFisher, for mass spectrometry we will rely on Applied Biosystems, and for DNA tethering materials we will rely on multiple manufacturers.”
FILING10-K0001193125-26-107281cik 0001835022
“For example, to image the exosomes we will rely on Malvern, to measure the size of the exosomes we will rely on Izon, for western blotting we will rely on ThermoFisher, for mass spectrometry we will rely on Applied Biosystems, and for DNA tethering materials we will rely on multiple manufacturers.”
FILING10-K0001193125-26-107281cik 0001835022
“For COYA 301, we have licensed the biologic cytokine from ARScience Biotherapeutics, Inc. and will rely on its manufacturing of the subject cytokine.”
FILING10-K0001193125-26-107281cik 0001835022
“For example, to image the exosomes we will rely on Malvern, to measure the size of the exosomes we will rely on Izon, for western blotting we will rely on ThermoFisher, for mass spectrometry we will rely on Applied Biosystems, and for DNA tethering materials we will rely on multiple manufacturers.”
FILING10-K0001193125-26-107281cik 0001835022
“For example, to image the exosomes we will rely on Malvern, to measure the size of the exosomes we will rely on Izon, for western blotting we will rely on ThermoFisher, for mass spectrometry we will rely on Applied Biosystems, and for DNA tethering materials we will rely on multiple manufacturers.”
FILING10-K0001193125-26-107281cik 0001835022
“For COYA 201, we rely on Terumo BCT to manufacture the Terumo Bioreactors to generate the appropriate number of expanded Treg cells.”
FILING10-K0001193125-26-107281cik 0001835022
“Key components of the technology utilized in our Treg Modalities have been in-licensed pursuant to an Amended and Restated Patent and Know How License Agreement, (the "Methodist License Agreement"), between us and The Methodist Hospital located in Houston, Texas (the "Methodist").”
FILING10-K0001193125-26-107281cik 0001835022
“Key components of the technology utilized in our Treg Modalities have been in-licensed pursuant to an Amended and Restated Patent and Know How License Agreement, (the "Methodist License Agreement"), between us and The Methodist Hospital located in Houston, Texas (the "Methodist").”
FILING10-K0001193125-26-107281cik 0001835022
“In August 2022, we entered into a License Agreement (the "ARS License Agreement") with ARS pursuant to which ARS granted us an option to, if we choose to exercise such option, to acquire an exclusive, royalty-bearing license for two patents regarding certain formulations of IL-2 (the product that serves as the basis for COYA 301), with the right to grant sublicenses through multiple tiers under these patents.”
FILING10-K0001193125-26-107281cik 0001835022
“Finally, our patent estate derived from our relationship with Carnegie Mellon included one pending patent application.”
FILING10-K0001193125-26-107281cik 0001835022
“In September of 2023 we licensed the exclusive, worldwide rights of a proprietary Exosome Engineering Technology from Carnegie Mellon University with potential applications across multiple indications, including neurodegeneration, autoimmune, and oncology (the "Carnegie Mellon License Agreement").”
FILING10-K0001193125-26-107281cik 0001835022
“In May 2023, we executed a Sponsored Research Agreement, or SRA, with Houston Methodist Research Institute, or HMRI, in which we agreed to fund approximately $0.5 million through May 2024.”
FILING10-K0001193125-26-107281cik 0001835022
“our patent estate derived from our relationship with the University of Nebraska includes two provisional patent applications.”
FILING10-K0001193125-26-107281cik 0001835022
“Both parties shall discuss in good faith and agree in writing on the terms of a commercial supply agreement for the purpose of supply of COYA 302 to Dr. Reddy's.”
FILING10-K0001193125-26-107281cik 0001835022
Watchlist prices, news filtered to it, and its next report on your desk.
Coya Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 4.61 · gapped below the open, then crossed back over prior close. High/low 4.69 at 2:15 pm ET, 4.50 at 10:45 am ET.
Coya Therapeutics, Inc. has 15 disclosed suppliers and 1 disclosed customer. Each one is named in an SEC filing, either Coya Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
COYA (Coya Therapeutics, Inc.) has 15 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: TMO +4.46%, in the health bundle.